A new biotech business SynaptixBio has been launched to tackle one of the world’s rarest neurodegenerative diseases.
SynaptixBio is working to develop the world’s first disease-modifying treatment for TUBB4a leukodystrophy, including H-ABC - a debilitating and potentially life-limiting condition.
To continue reading please go to the article on Uganda ScieGirl